GO:0048246 macrophage chemotaxis: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048246 (macrophage chemotaxis) is defined as the directed movement of a macrophage in response to an external stimulus.
• Macrophage chemotaxis is a multi-step process that includes gradient sensing, actin cytoskeletal rearrangement, adhesion turnover, and rear retraction.
• Tyrosine phosphorylation and Rho-family GTPase signaling are central regulatory nodes in macrophage chemotaxis.
• Macrophage chemotaxis is implicated in liver ischemia/reperfusion injury, atherosclerosis, Staphylococcus aureus infection, and non-alcoholic steatohepatitis.
• Time-lapse imaging of mouse macrophages is a standard experimental approach for quantifying chemotactic behavior.
• CRISPR-based knockout, knock-in, point-mutation, and overexpression models enable causal testing of candidate genes in macrophage chemotaxis.
Description
Macrophage chemotaxis (GO:0048246) is the directed migration of macrophages along chemical gradients toward sites of injury, infection, or inflammation. This process is fundamental to innate immunity because it positions macrophages at the right place and time to phagocytose pathogens, clear debris, and orchestrate tissue repair. The QuickGO definition states that GO:0048246 encompasses the movement of a macrophage in response to an external stimulus, and this definition is supported by classical studies of macrophage accumulation in inflammatory lesions. At the cellular level, chemotaxis requires coordinated sensing of chemoattractants, polarization of the actin cytoskeleton, and dynamic adhesion to the extracellular matrix. Signaling through tyrosine phosphorylation cascades and Rho-family GTPases provides the molecular logic that converts receptor occupancy into directional movement. Because dysregulated macrophage chemotaxis contributes to diverse pathologies, including ischemia/reperfusion injury, atherosclerosis, and infection, the term is a high-value target for mechanistic and translational research. Recent work has also highlighted metabolic and epigenetic control of macrophage chemotaxis, for example through glycolysis-mediated HMGB1 lactylation in hepatocytes. Nanoplatform-based strategies that reprogram macrophage chemotaxis are now being explored for non-alcoholic steatohepatitis therapy. Understanding GO:0048246 therefore bridges basic cell biology, immunology, and therapeutic development.
macrophage chemotaxis At A Glance
| GO ID | GO:0048246 |
|---|---|
| GO term | macrophage chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Definition | The movement of a macrophage in response to an external stimulus. |
| Major function | Directed migration of macrophages along chemical gradients to sites of injury, infection, or inflammation |
| Key signaling nodes | Tyrosine phosphorylation and Rho-family GTPase pathways |
| Representative disease links | Liver ischemia/reperfusion injury, atherosclerosis, Staphylococcus aureus infection, non-alcoholic steatohepatitis |
| Common experimental readout | Time-lapse imaging of mouse macrophage chemotaxis |
What Is GO:0048246?
GO:0048246 (macrophage chemotaxis) is a biological process term describing the movement of a macrophage in response to an external stimulus. In practice, this means a macrophage detects a chemical gradient and migrates directionally toward or away from the source, a behavior that is distinct from random motility and from chemokinesis. The term is used in gene ontology annotation to capture the directed, stimulus-dependent locomotion of macrophages, and it is supported by classical observations of macrophage accumulation during inflammation.
Why Is macrophage chemotaxis Important in Cell Biology?
Macrophage chemotaxis is important because it determines whether macrophages reach the correct tissue location to perform immune surveillance, pathogen clearance, and wound healing. When this process is dysregulated, macrophages can accumulate inappropriately and drive tissue damage, as seen in liver ischemia/reperfusion injury where hepatocyte HSPA12A inhibits macrophage chemotaxis and activation. Conversely, insufficient or misdirected chemotaxis can impair host defense against pathogens such as Staphylococcus aureus. The process is also a therapeutic target: chemotaxis-guided nanoplatforms have been developed to reprogram macrophages in non-alcoholic steatohepatitis, and deficiency of the lncRNA MERRICAL abrogates macrophage chemotaxis in diabetes-associated atherosclerosis. Because chemotaxis integrates receptor signaling, cytoskeletal dynamics, and metabolic state, it is a rich area for CRISPR-based functional genomics.
• Macrophage chemotaxis is essential for innate immune defense and pathogen clearance.
• It contributes to inflammatory tissue injury, including liver ischemia/reperfusion injury.
• It is a driver of atherosclerosis in diabetes, as shown by lncRNA MERRICAL deficiency.
• It is a therapeutic target in non-alcoholic steatohepatitis via macrophage reprogramming.
• Tyrosine phosphorylation and Rho GTPase signaling are core regulatory mechanisms.
• Time-lapse imaging provides quantitative readouts of chemotactic behavior.
• Classical studies established macrophage chemotaxis as a hallmark of inflammation.
• CRISPR models enable causal testing of candidate genes in chemotaxis.
What Happens During macrophage chemotaxis?
Gradient sensing and receptor activation
In simple terms: The macrophage first smells the chemical trail and switches on receptors that detect it.
Macrophage chemotaxis begins when surface receptors bind chemoattractants, converting an external chemical gradient into intracellular signals. This sensing step is coupled to tyrosine phosphorylation cascades that propagate the signal inward. Classical studies of inflammation established that macrophages accumulate along chemotactic gradients in vivo.
Actin cytoskeletal polarization
In simple terms: The cell builds a front end that pushes forward and a back end that lets go.
After receptor activation, the macrophage polarizes its actin cytoskeleton, forming lamellipodia at the leading edge and retracting the rear. Rho-family GTPases and tyrosine phosphorylation regulate this rearrangement. This step converts chemical information into mechanical force for movement.
Adhesion turnover and traction
In simple terms: The cell grips the surface at the front and releases at the back to move forward.
Macrophage chemotaxis requires dynamic adhesion to the extracellular matrix, with new adhesions forming at the front and old adhesions disassembling at the rear. Tyrosine phosphorylation of adhesion-associated proteins is a key regulatory event in this turnover.
Metabolic and epigenetic modulation
In simple terms: The cell's metabolism and gene-control marks can tune how strongly it migrates.
Recent work shows that hepatocyte HSPA12A inhibits macrophage chemotaxis and activation by suppressing glycolysis-mediated HMGB1 lactylation and secretion. This links metabolic and epigenetic states to the chemotactic capacity of macrophages. Such crosstalk expands the regulatory landscape of GO:0048246 beyond classical signaling.
Resolution and retention at the target site
In simple terms: Once the macrophage arrives, it stops and stays to do its job.
At the target site, macrophages transition from migratory to effector states, contributing to pathogen clearance or tissue repair. In Staphylococcus aureus infection, macrophage recruitment and retention are critical for bacterial control. Dysregulation of this resolution step can lead to chronic inflammation.
Key Genes Involved in GO:0048246 macrophage chemotaxis
The following genes and proteins have been experimentally linked to macrophage chemotaxis or its regulation in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HSPA12A | Hepatocyte protein that inhibits macrophage chemotaxis and activation via glycolysis-mediated HMGB1 lactylation | Liver ischemia/reperfusion injury model |
| HMGB1 | Secreted alarmin whose lactylation and secretion modulate macrophage chemotaxis | Inflammation and liver injury |
| MERRICAL | Long non-coding RNA required for macrophage chemotaxis in diabetes-associated atherosclerosis | Atherosclerosis and diabetes models |
| Rho-family GTPases | Regulate actin cytoskeletal polarization during chemotaxis | Cell migration signaling studies |
| Tyrosine kinases | Mediate phosphorylation cascades in macrophage chemotaxis and phagocytosis | Signaling and inhibitor studies |
| Chemokine receptors | Detect external chemoattractant gradients | Inflammation and infection models |
| Integrins | Mediate adhesion turnover during migration | Extracellular matrix interaction studies |
| Actin regulators | Control lamellipodia formation and rear retraction | Cytoskeleton dynamics research |
| Phosphatases | Counterbalance tyrosine phosphorylation in chemotaxis | Signaling balance studies |
| S. aureus surface proteins | Modulate macrophage recruitment during infection | Host-pathogen interaction models |
| Glycolysis enzymes | Support metabolic requirements for chemotaxis | Metabolic regulation studies |
| Lactylation writers/erasers | Regulate HMGB1 lactylation and secretion | Epigenetic and metabolic crosstalk |
| Nanoplatform targets | Reprogram macrophage chemotaxis in NASH | Therapeutic delivery studies |
| Imaging reporters | Enable time-lapse tracking of macrophage chemotaxis | Live-cell imaging assays |
| Inflammation mediators | Drive macrophage accumulation in lesions | Classical inflammation research |
How Is macrophage chemotaxis Regulated?
Macrophage chemotaxis is regulated at multiple levels. Tyrosine phosphorylation cascades provide rapid, reversible control of signaling proteins involved in migration and phagocytosis. Rho-family GTPases coordinate actin cytoskeletal rearrangement and adhesion turnover. Metabolic and epigenetic regulation has emerged as an additional layer: hepatocyte HSPA12A suppresses glycolysis-mediated HMGB1 lactylation and secretion, thereby inhibiting macrophage chemotaxis. The long non-coding RNA MERRICAL is required for macrophage chemotaxis in diabetes-associated atherosclerosis, indicating lncRNA-mediated regulation. Chemotaxis-guided nanoplatforms can also modulate macrophage behavior for therapeutic benefit in non-alcoholic steatohepatitis.
macrophage chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSPA12A | Liver ischemia/reperfusion injury | Hepatocyte-specific knockout or overexpression in mouse liver I/R |
| MERRICAL | Diabetes-associated atherosclerosis | lncRNA knockout in diabetic atherosclerosis mouse models |
| HMGB1 | Inflammation and liver injury | Lactylation-site point mutation knock-in |
| Chemokine receptors | Staphylococcus aureus infection | Receptor knockout in macrophage infection models |
| Nanoplatform targets | Non-alcoholic steatohepatitis | Macrophage reprogramming in NASH models |
Liver ischemia/reperfusion injury
Hepatocyte HSPA12A inhibits macrophage chemotaxis and activation to attenuate liver ischemia/reperfusion injury by suppressing glycolysis-mediated HMGB1 lactylation and secretion. This identifies macrophage chemotaxis as a modifiable node in hepatic ischemic injury.
Diabetes-associated atherosclerosis
Deficiency of the lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis, linking GO:0048246 to vascular disease. This suggests that lncRNA-directed chemotaxis contributes to plaque formation in diabetes.
Staphylococcus aureus infection
Macrophages are central to Staphylococcus aureus infection, where chemotaxis determines recruitment to infected sites. Impaired macrophage chemotaxis can compromise bacterial clearance.
Non-alcoholic steatohepatitis
A chemotaxis-guided nanoplatform has been developed for non-alcoholic steatohepatitis therapy via macrophage reprogramming, hepatoprotection, and gut microbiome modulation. This highlights macrophage chemotaxis as a therapeutic target in metabolic liver disease.
From macrophage chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is HSPA12A required for inhibition of macrophage chemotaxis? | HSPA12A knockout or overexpression in hepatocytes |
| Does HMGB1 lactylation control macrophage chemotaxis? | HMGB1 lactylation-site point mutation knock-in |
| Is MERRICAL required for chemotaxis in atherosclerosis? | MERRICAL knockout in diabetic atherosclerosis models |
| Which tyrosine phosphorylation events regulate chemotaxis? | Kinase/phosphatase knockout or point-mutation macrophages |
| How do Rho GTPases control actin polarization? | Rho GTPase knockout or tagged knock-in macrophages |
| Can nanoplatforms reprogram macrophage chemotaxis? | Chemotaxis-guided nanoplatform in NASH models |
How to Study the macrophage chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Time-lapse imaging | Directional movement and speed of macrophages | Quantifying chemotaxis in vitro |
| Phospho-tyrosine assays | Tyrosine phosphorylation events | Mapping signaling in chemotaxis |
| Lactylation assays | HMGB1 lactylation and secretion | Metabolic-epigenetic crosstalk in liver injury |
| In vivo inflammation models | Macrophage accumulation in tissue | Classical inflammation studies |
| Infection models | Macrophage recruitment during infection | Staphylococcus aureus host-pathogen studies |
| Atherosclerosis models | Chemotaxis in vascular disease | Diabetes-associated atherosclerosis research |
| Nanoplatform delivery | Macrophage reprogramming in NASH | Therapeutic targeting of chemotaxis |
Time-lapse imaging of macrophage chemotaxis
Time-lapse imaging of mouse macrophages is a standard method to visualize and quantify chemotactic movement in response to gradients. This approach captures directionality, speed, and persistence of migration.
Tyrosine phosphorylation analysis
Because tyrosine phosphorylation regulates macrophage chemotaxis and phagocytosis, phospho-specific assays are used to map signaling events. These readouts help identify kinases and phosphatases that control migration.
Metabolic and lactylation assays
Glycolysis-mediated HMGB1 lactylation and secretion can be measured to link metabolism to chemotaxis. Such assays are useful in liver injury models where HSPA12A suppresses chemotaxis.
In vivo inflammation and infection models
Macrophage chemotaxis is studied in inflammation and infection models, including Staphylococcus aureus infection and liver ischemia/reperfusion injury. These models connect molecular mechanisms to tissue-level outcomes.
How CRISPR Can Be Used to Study GO:0048246 macrophage chemotaxis
Knockout
CRISPR knockout of candidate genes such as HSPA12A or MERRICAL can test whether they are required for macrophage chemotaxis in disease models. Knockout macrophages or hepatocytes provide causal evidence for gene function in GO:0048246.
Point Mutation
Point-mutation knock-in can dissect specific residues, such as lactylation sites on HMGB1, to determine their role in chemotaxis. This approach refines mechanistic understanding beyond simple loss-of-function.
Knock-in
Tagged knock-in of chemotaxis-related proteins enables live-cell imaging and biochemical tracking of their dynamics. Knock-in reporters can be combined with time-lapse imaging to quantify migration.
Overexpression
Overexpression of genes such as HSPA12A can suppress macrophage chemotaxis, as shown in liver ischemia/reperfusion injury models. Overexpression models are useful for gain-of-function studies of chemotaxis regulators.
How EDITGENE Supports macrophage chemotaxis Research
Researchers studying macrophage chemotaxis-related genes often need to determine whether a candidate gene is causally involved in directed migration or merely correlated with it. CRISPR-based models provide the necessary causal evidence by enabling precise knockout, point mutation, knock-in, and overexpression in relevant cell types. EDITGENE supports these workflows with validated cell model generation and functional screening services tailored to GO:0048246 research.
Contact EDITGENE today to design your custom CRISPR model for macrophage chemotaxis research.
Frequently Asked Questions About macrophage chemotaxis
What is macrophage chemotaxis (GO:0048246)?
Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus, as defined by GO:0048246.
What genes are involved in macrophage chemotaxis?
Genes and factors include HSPA12A, HMGB1, MERRICAL, Rho-family GTPases, and tyrosine kinases.
How is macrophage chemotaxis measured?
Time-lapse imaging of mouse macrophages is a standard method for measuring chemotactic movement.
Why is macrophage chemotaxis important in disease?
It contributes to liver ischemia/reperfusion injury, atherosclerosis, Staphylococcus aureus infection, and non-alcoholic steatohepatitis.
What signaling pathways regulate macrophage chemotaxis?
Tyrosine phosphorylation and Rho-family GTPase signaling are central regulators.
Can CRISPR be used to study macrophage chemotaxis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of chemotaxis genes.
What is the role of HMGB1 in macrophage chemotaxis?
HMGB1 lactylation and secretion modulate macrophage chemotaxis in liver injury models.
What is MERRICAL and how does it relate to chemotaxis?
MERRICAL is a long non-coding RNA required for macrophage chemotaxis in diabetes-associated atherosclerosis.
How does HSPA12A affect macrophage chemotaxis?
Hepatocyte HSPA12A inhibits macrophage chemotaxis and activation via suppressing glycolysis-mediated HMGB1 lactylation.
What models are used to study macrophage chemotaxis?
Models include time-lapse imaging, inflammation and infection models, atherosclerosis models, and nanoplatform-based NASH models.
Conclusion
GO:0048246 (macrophage chemotaxis) is a central biological process that governs how macrophages navigate to sites of injury, infection, and inflammation. Its regulation involves tyrosine phosphorylation, Rho-family GTPases, metabolic and epigenetic mechanisms, and lncRNAs such as MERRICAL. Dysregulated chemotaxis contributes to liver ischemia/reperfusion injury, atherosclerosis, Staphylococcus aureus infection, and non-alcoholic steatohepatitis. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with time-lapse imaging and functional screening, provide powerful tools to dissect this process. EDITGENE offers integrated services to accelerate discovery in macrophage chemotaxis research.
References
- 1. Du S et al.. 2023. Hepatocyte HSPA12A inhibits macrophage chemotaxis and activation to attenuate liver ischemia/reperfusion injury via suppressing glycolysis-mediated HMGB1 lactylation and secretion of hepatocytes.. Theranostics 13(11):3856-3871 PMID: 37441587
- 2. Hayashi H et al.. 1985. Chemotaxis of macrophage in inflammation.. Comp Immunol Microbiol Infect Dis 8(2):73-87 PMID: 2417777
- 3. Pan X et al.. 2026. Chemotaxis-guided nanoplatform for non-alcoholic steatohepatitis therapy via macrophage reprogramming, hepatoprotection and gut microbiome modulation.. Biomaterials 326:123694 PMID: 40957387
- 4. van den Bos E et al.. 2020. Time-lapse Imaging of Mouse Macrophage Chemotaxis.. J Vis Exp PMID: 32310228
- 5. Pidwill GR et al.. 2020. The Role of Macrophages in Staphylococcus aureus Infection.. Front Immunol 11:620339 PMID: 33542723
- 6. Jones GE. 2000. Cellular signaling in macrophage migration and chemotaxis.. J Leukoc Biol 68(5):593-602 PMID: 11073096
- 7. Park H et al.. 2011. Regulation of tyrosine phosphorylation in macrophage phagocytosis and chemotaxis.. Arch Biochem Biophys 510(2):101-11 PMID: 21356194
- 8. Chen J et al.. 2024. Deficiency of lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis.. Cell Rep 43(3):113815 PMID: 38428421
